Obalon Therapeutics News Releases http://investor.obalon.com/ Obalon Therapeutics News Releases en Obalon Appoints Bob MacDonald as Chief Retail Officer http://investor.obalon.com/news-releases/news-release-details/obalon-appoints-bob-macdonald-chief-retail-officer Experienced executive with successful track record of leading strategic growth initiatives, including national chain of retail cosmetic surgery clinics SAN DIEGO , June 10, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the Mon, 10 Jun 2019 08:30:00 -0400 Obalon Therapeutics News Releases 8086 Obalon Announces Issuance of First U.S. Patent Covering Its Proprietary Navigation System http://investor.obalon.com/news-releases/news-release-details/obalon-announces-issuance-first-us-patent-covering-its Expands the Company’s intellectual property estate to 20 issued US patents SAN DIEGO , June 04, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon Tue, 04 Jun 2019 08:30:00 -0400 Obalon Therapeutics News Releases 8076 Obalon Therapeutics, Inc. Prices $3,000,000 Registered Direct Offering http://investor.obalon.com/news-releases/news-release-details/obalon-therapeutics-inc-prices-3000000-registered-direct SAN DIEGO , May 23, 2019 (GLOBE NEWSWIRE) -- OBALON THERAPEUTICS, INC. (NASDAQ: OBLN) (“Obalon” or the “Company”) , a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today Thu, 23 May 2019 08:30:00 -0400 Obalon Therapeutics News Releases 8031 Expanded Clinical Data Set for the Obalon Balloon System Presented at DDW 2019 http://investor.obalon.com/news-releases/news-release-details/expanded-clinical-data-set-obalon-balloon-system-presented-ddw Results from over 1,400 patients treated across 143 sites with Obalon’s non-surgical weight loss solution continue to affirm the safety and effectiveness of the Obalon Balloon System SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. Tue, 21 May 2019 16:01:00 -0400 Obalon Therapeutics News Releases 8021 Obalon Announces Receipt of Delisting Notification Letters from Nasdaq http://investor.obalon.com/news-releases/news-release-details/obalon-announces-receipt-delisting-notification-letters-nasdaq SAN DIEGO , May 17, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written Fri, 17 May 2019 16:01:00 -0400 Obalon Therapeutics News Releases 8011 Obalon Engages Cowen to Explore Financial and Strategic Alternatives http://investor.obalon.com/news-releases/news-release-details/obalon-engages-cowen-explore-financial-and-strategic SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained Thu, 11 Apr 2019 08:00:00 -0400 Obalon Therapeutics News Releases 7981 Obalon Announces Restructuring to Streamline Operations & Cash Use http://investor.obalon.com/news-releases/news-release-details/obalon-announces-restructuring-streamline-operations-cash-use SAN DIEGO , April 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced an organizational Wed, 03 Apr 2019 08:30:00 -0400 Obalon Therapeutics News Releases 7976 Obalon Announces Upcoming Conference Presentations http://investor.obalon.com/news-releases/news-release-details/obalon-announces-upcoming-conference-presentations-1 SAN DIEGO , March 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang , Thu, 14 Mar 2019 09:00:00 -0400 Obalon Therapeutics News Releases 7961 Obalon Announces First Commercial Use of Navigation and Touch Products for Obalon Balloon Administration http://investor.obalon.com/news-releases/news-release-details/obalon-announces-first-commercial-use-navigation-and-touch SAN DIEGO , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve Wed, 27 Feb 2019 09:00:00 -0500 Obalon Therapeutics News Releases 7946 Obalon Announces First Commercial Shipment of its Navigation Balloon Placement System with Touch Inflation Dispenser http://investor.obalon.com/news-releases/news-release-details/obalon-announces-first-commercial-shipment-its-navigation Obalon Navigation System™ with Touch™ Inflation Dispenser are intended to increase adoption of the Obalon Balloon by improving ease of administration and eliminating the need for x-ray imaging on placement SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. Fri, 22 Feb 2019 08:25:00 -0500 Obalon Therapeutics News Releases 7936